REGENERON PHARMACEUTICALS, INC. Current Income Tax Expense (Benefit)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Current Income Tax Expense (Benefit) of $1.51 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. current income tax expense (benefit) for the quarter ending 2014-03-31 was $112.58M.
- REGENERON PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2025 was $1.51B, a 34.38% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2024 was $1.12B, a 3.79% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2023 was $1.08B, a 14.47% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. current income tax expense (benefit) for fiscal 2022 was $1.27B, a 9.36% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $1.51B 10-K · filed 2026-02-04 | ||
| 2024-12-31 | $1.12B 10-K · filed 2026-02-04 | ||
| 2023-12-31 | $1.08B 10-K · filed 2026-02-04 | ||
| 2022-12-31 | $1.27B 10-K · filed 2025-02-05 | ||
| 2021-12-31 | $1.40B 10-K · filed 2024-02-05 | ||
| 2020-12-31 | $221.60M 10-K · filed 2023-02-06 | ||
| 2019-12-31 | $443.90M 10-K · filed 2022-02-07 | ||
| 2018-12-31 | $249.10M 10-K · filed 2021-02-08 | ||
| 2017-12-31 | $561.00M 10-K · filed 2020-02-07 | $560.99M 10-K · filed 2018-02-08 | |
| 2016-12-31 | $794.40M 10-K · filed 2019-02-07 | $794.37M 10-K · filed 2017-02-09 | |
| 2015-12-31 | $719.13M 10-K · filed 2018-02-08 | ||
| 2014-12-31 | $468.63M 10-K · filed 2017-02-09 | $478.97M 10-K · filed 2015-02-12 | |
| 2014-03-31 | $112.58M 10-Q · filed 2015-05-07 | ||
| 2013-12-31 | $220.45M 10-K · filed 2016-02-11 | $225.40M 10-K · filed 2014-02-13 | |
| 2012-12-31 | $4.31M 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |